Seeking Alpha
06 Jul 2026, 05:51 UTC · 1h ago
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
06 Jul 2026, 05:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Silevertinib demonstrated a 60% overall response rate (ORR) and 86% CNS ORR in Phase 2 trials for NSCLC. — Strong clinical efficacy data for a lead asset is the primary driver of valuation and probability of regulatory approval in biotech.
+0.80Black Diamond Therapeutics is currently trading below its cash value. — Trading below cash provides a fundamental floor for the stock price, reducing downside risk for investors.
+0.60The company maintains a cash runway of $118 million and potential non-dilutive milestone payments. — Adequate liquidity reduces the immediate need for dilutive equity raises, protecting existing shareholder value.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company has a 'Buy' rating due to strong Phase 2 trial results, a significant cash runway, and a compelling risk/reward profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
